王鵬飛

發布時間：2021-07-09瀏覽次數：8671

教師基本信息

姓名：王鵬飛(Pengfei Wang)

職稱：正高

職務：青年研究員(Junior Professor)

電子郵箱：pengfei_wang@fudan.edu.cn

辦公地點：狗万外围充值 江灣校區万博体育分 E501-4

個人網頁/課題組主頁：https://scholar.google.com/citations?user=fWjlGn8AAAAJ&hl=en

研究方向：

抗病毒藥物和疫苗

Antiviral therapeutics and vaccines

個人簡介：

王鵬飛，2006-2010年就讀於北京師範大學獲得學士學位；2010-2015年就讀於万博英超狼队网官方网 並獲得博士學位； 2015-2019年於美國洛克菲勒大學從事博士後研究；2020-2021年任美國哥倫比亞大學助理研究員，2021年7月起任万博英超狼队网官方网 青年研究員、博士生導師。入選科睿唯安（Clarivate）2023年度“全球高被引科學家”和愛思維爾（Elsevier）“2023全球前2%頂尖科學家榜單”；被聘為狗万外围充值 首屆“小米青年學者”；曾獲“上海科技青年引領35人計劃”提名獎、阿裏巴巴達摩院“青橙優秀入圍獎”等。長期從事新發傳染病防治方麵的研究，包括針對病毒的抗體和藥物篩選、疫苗評估等。至今發表論文60多篇；累計引用9000餘次；其中以（共同）第一或通訊作者身份在Nature (3篇)、Nat. Rev. Immun.、Cell Host & Microbe (3篇)、Cell Discovery (3篇)、Proc. Natl. Acad. Sci. U.S.A.等期刊發表論文20多篇。

Pengfei Wang is a Junior Professor and PhD supervisor at Fudan University. From 2006 to 2010, he studied at Beijing Normal University, where he obtained his bachelor's degree. He then pursued his doctoral studies at the School of Life Sciences, Fudan University from 2010 to 2015. From 2015 to 2019, he carried out postdoctoral research at Rockefeller University in the United States. He served as an Associate Researcher Scientist at Columbia University from 2020 to 2021. Starting in July 2021, he assumed the position of Junior Professor at the School of Life Sciences, Fudan University.

Dr. Wang has been listed in Clarivate’s “Highly Cited Researcher 2023” and Elsevier/Stanford’s “World's Top 2% Scientists 2023”. He has been honored with awards such as the nomination for the "2022 Shanghai Science & Technology 35 under 35" and the outstanding candidate award of 2022 Alibaba DAMO Academy Young Fellow. He has been deeply involved in research related to the prevention and treatment of emerging infectious diseases, including the screening of antibodies and drugs against viruses, vaccine evaluation, and functional cure research for HIV/AIDS.

To date, he has published over 60 papers, which have been cited more than 9,000 times. Of these, over 20 were published in leading journals such as Nature (3), Nat. Rev. Immun., Cell Host & Microbe (3), Cell Discovery (3), and Proc. Natl. Acad. Sci. U.S.A., where he served as the (co-)first author or corresponding author.

授課情況：

感染與免疫（H）

Infection & Immunology（H）

招生專業：

遺傳學(Genetics)、微生物學(Microbiology)、免疫學(Immunology)

科研項目：

科技部重點研發、國自然麵上項目等

National Key Research and Development Program of China, National Natural Science Foundation of China

獲獎情況：

科睿唯安（Clarivate）2023年度“全球高被引科學家”、愛思維爾（Elsevier）“2023全球前2%頂尖科學家榜單”

World's Top 2% Scientists 2023 (Elsevier/Stanford)

- Clarivate Highly Cited Researcher 2023

代表性論文和論著：

  1. Wang X, Jiang S, Ma W, Li X, Wei K, Xie F, Zhao C, Zhao X, Wang S, Li C, Qiao R, Cui Y, Chen Y, Li J, Cai G, Liu C, Yu J, Li J, Hu Z, Zhang W, Jiang S, Li M#, Zhang Y#, Wang P#. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.  Cell Host & Microbe, 2023, DOI: 10.1016/j.chom.2023.11.012.

  2. Wang X, Jiang S, Jiang S, Li X, Ai J, Lin K, Lv S, Zhang S, Li M, Li J#, Dai L#, Hu Z#, Zhang W#, Zhang Y#, Wang P#. Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by Breakthrough Infection Sera from Previous and Recent Waves in China. Cell Discovery, 2023, 9(1):64.

  3. Wang X, He X, Jiang S, Fu Z, Jiang S, Zhao X, Zhao C, Li Y, Li D, Zhang W, Ai J#, Zhang Y#, Xu C#, Wang P#. Limited enhancement of antibody and B-cell responses to prototype booster vaccination following SARS-CoV-2 Delta breakthrough infection. Journal of Medical Virology. 2023; 95(2): e28540.

  4. Chen Y, Zhao X, Zhou H, Zhu H, Jiang S#, Wang P#. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nature reviews immunology. 2023,23, 189–199.

  5. Wang H, Xue Q, Zhang H, Yuan G, Wang X, Sheng K, Li C, Cai J, Sun Y, Zhao J, Lu J, Fang S, Yang Y, Zhang Y, Huang Y, Wang J, Xu JH, Jiang MX, Wang X, Shen L, Liu Y, Liu Q, Zhang Q, Wang S, Wang P#, Qiu C#, Ai J#, Zhang W. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination. Emerging Microbes & Infections. 2023,5:2249121.

  6. Qiao R, Tang W, Li J, Li C, Zhao C, Wang X, Li M, Cui Y, Chen Y, Cai G, Wu Q, Zhao X#, Wang P#. Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. Virology. 2023, 585:205-14.

  7. Wang X, Li M, Lu P, Li C, Zhao C, Zhao X, Qiao R, Cui Y, Chen Y, Li J, Cai G, Wang P#. In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG. Pathogens. 2023, 30;12(9):1108.

  8. Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z#, Zhang W#, Wang P#. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 sub-lineages. Cell Host & Microbe, 2022, 10;30(8):1077-1083.e4.

  9. Wang X, Ai J, Li X, Zhao X, Wu J, Zhang H, He X, Zhao C, Qiao R, Li M, Cui Y, Hu Z#, Xu C#, Zhang W#, Wang P#. Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera. Cell Discovery, 2022. doi: 10.1038/s41421-022-00472-5.

  10. Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M, Cui Y, Chen Y, Yang L, Liu J, Zhu H, Jiang S, Wang P#. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes & Infections. 2022;11(1):477-481.

  11. Zhao X, Li C, Chiu MC, Qiao R, Jiang S, Wang P#, Zhou J#. Rock1 is a novel host dependency factor of human enterovirus A71: implication as a drug target. Journal of Medical Virology. 2022. doi: 10.1002/jmv.27975.

  12. Wang X, Zhao X, Cui Y, Qiao R, Li M, Chen Y, Yang L, Jiang S, Wang P#. Neutralization of distinct Omicron sublineages by longitudinal vaccination sera. Journal of Medical Virology 2022. doi: 10.1002/jmv.28017.

  13. Wang P*, Nair MS*, Liu L*, Iketani S*, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021, 593, 130–135.

  14. Wang P*#, Casner RG*, Nair MS*, Wang M, Yu J, Cerutti G, Liu L, Kwong PD, Huang Y, Shapiro L#, Ho DD#. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. Cell Host & Microbe, 2021, 29 (5), 747-751. e4.

  15. Liu L*, Wang P*(Equal contribution), Nair MS*, Yu J*, Rapp MA*, Wang Q*, Luo Y, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike. Nature, 2020, 584, 450–456.

  16. Han Y*, Duan X*, Yang L*, Nilsson-Payant BE*, Wang P*(Equal contribution), Duan F*, Tang X*, Yaron TM*, Zhang T, Uhl S, Bram Y, Richardson C, Zhu J, Zhao Z, Redmond D, Houghton S, Nguyen D, Xu D, Wang X, Jessurun J, Borczuk A, Huang Y, Johnson JL, Liu Y, Xiang J, Wang H, Cantley LC, tenOever BR, Ho DD, Pan FC, Evans T, Chen HJ, Schwartz RE, Chen S. Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids. Nature. 2021, 589, 270–275.

  17. Wang P, Gajjar MR, Yu J, Padte NN, Gettie A, Blanchard JL, Russell-Lodrigue K, Liao LE, Perelson AS, Huang Y, Ho DD. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. PNAS. 2020, 117(30):18002-18009.

  18. Wang P, Casner RG, Nair MS, Yu J, Guo Y, Wang M, Chan JF, Cerutti G, Iketani S, Liu L, Sheng Z, Chen Z, Yuen KY, Kwong PD, Huang Y, Shapiro L, Ho DD. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerging Microbes & Infections. 2022, 11(1):147-157.

  19. Wang P*, Liu L*, Nair MS*, Yin MT*, Luo Y, Wang Q, Yuan T, Mori K, Solis AG, Yamashita M, Lawrence J. Purpura LJ, Laracy JC, Yu J, Sodroski JG, Huang Y, Ho DD. SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease. Emerging Microbes & Infections. 2020, 9(1):2091-2093.

  20. Wang P. Anti-HIV Passive Immunization in Animal Models. Journal of HIV & Retro Virus. 2018, 4 (1): 4.

  21. Wang P, Lu P, Qu X, Shen Y, Zeng H, Zhu X, Zhu Y, Li X, Wu H, Xu J, Lu H, Ma Z, Zhu H. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. Scientific Reports. 2017, 25;7(1):9451.

  22. Wang P, Qu X, Zhou X, Shen Y, Ji H, Fu Z, Deng J, Lu P, Yu W, Lu H, Zhu H. Two cellular microRNAs, miR-196b and miR-1290, contribute to HIV-1 latency. Virology. 2015, 486:228-38.

  23. Wang P, Qu X, Wang X, Zhu X, Zeng H, Chen H, Zhu H. Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5′-LTR promoter. Gene Therapy. 2014, 21(5):490-495.

  24. Wang P, Qu X, Wang X, Liu L, Zhu X, Zeng H, Zhu H. As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB. Antiviral Research. 2013, 100 (3): 688-697.

  25. Qu X*, Wang P*(Equal contribution), Ding D, Li L, Wang H, Ma L, Zhou X, Liu S, Lin S, Wang X, Zhang G, Liu S, Liu L, Wang J, Zhang F, Lu D, Zhu H. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Research. 2013, 41 (16): 7771-7782.  

  26. Jiao Y*, Wang P*(Equal contribution), Zhang H, Zhang T, Zhang Y, Zhu H, Wu H. HIV-1 Co-Receptor Usage Based on V3 Loop Sequence Analysis: Preferential Suppression of CXCR4 Virus Post HAART? Immunological Investigations 2011, 40(6):597-613.







Baidu
map